Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension
- 10 January 2008
- journal article
- research article
- Published by Elsevier
- Vol. 51 (2) , 161-169
- https://doi.org/10.1016/j.jacc.2007.09.031
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Pulmonary hypertension in childrenCurrent Paediatrics, 2006
- Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defectsEuropean Journal of Clinical Investigation, 2006
- Response to bosentan in children with pulmonary hypertensionHeart, 2006
- Preliminary Experience With Bosentan as Initial Therapy in Childhood Idiopathic Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2006
- Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolThorax, 2005
- Effects of Long-Term Bosentan in Children With Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentanThe American Journal of Cardiology, 2004
- Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in childrenPediatric Pulmonology, 2003
- Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusionHeart, 2001